Premium Nahrungsergänzungsmittel | artgerecht

KRAS G12C – Mutation, Therapy & Significance

KRAS G12C is a specific genetic mutation in the KRAS gene found in various cancers and represents a key target for precision oncology and targeted cancer therapies.

Regular tips about health Regular tips about health

Things worth knowing about "KRAS G12C"

KRAS G12C is a specific genetic mutation in the KRAS gene found in various cancers and represents a key target for precision oncology and targeted cancer therapies.

What is KRAS G12C?

KRAS G12C refers to a specific somatic point mutation in the KRAS gene (Kirsten Rat Sarcoma Viral Proto-Oncogene). In this mutation, the amino acid glycine at position 12 of the KRAS protein is replaced by cysteine (G12C = Glycine to Cysteine at codon 12). The KRAS gene belongs to the RAS oncogene family and plays a central role in regulating cell growth, division, and differentiation. This mutation causes the KRAS protein to remain permanently active, continuously promoting uncontrolled cell growth – a key driver of cancer development.

Prevalence and Clinical Significance

KRAS mutations are among the most common oncogenic mutations in human cancers. The KRAS G12C variant occurs most frequently in the following cancer types:

Non-small cell lung cancer (NSCLC): approximately 13–14% of all cases
Colorectal cancer: approximately 3–4% of all cases
Pancreatic cancer: in smaller proportions
Other solid tumors

Compared to other KRAS mutations (e.g., G12D or G12V), the G12C variant is particularly significant because the unique chemical reactivity of cysteine enables targeted pharmacological inhibition.

Biological Mechanism of Action

The KRAS protein is a GTPase that cycles between an active (GTP-bound) and an inactive (GDP-bound) state. Under normal conditions, KRAS is activated by external signals and then deactivated once its function is complete. In the G12C mutation, this regulatory mechanism is disrupted: the protein remains locked in the active GTP-bound state, continuously transmitting growth signals through downstream pathways such as the MAPK/ERK pathway and the PI3K/AKT pathway. This results in uncontrolled cell proliferation, inhibition of programmed cell death (apoptosis), and ultimately tumor formation and progression.

Diagnosis and Testing Methods

Detection of a KRAS G12C mutation is performed through molecular pathology testing of tumor tissue or blood (known as liquid biopsy). The following methods are used:

Next-Generation Sequencing (NGS): comprehensive analysis of the tumor genome
PCR-based methods (e.g., quantitative real-time PCR, allele-specific PCR)
Liquid biopsy: detection of circulating tumor DNA (ctDNA) in blood

Mutation testing is critical for treatment planning, as only patients with a confirmed KRAS G12C mutation benefit from specific inhibitors.

Targeted Therapy with KRAS G12C Inhibitors

For many years, KRAS mutations were considered “undruggable” because the KRAS protein appeared to lack a suitable binding pocket for conventional inhibitors. However, the unique reactivity of the cysteine residue at position 12 enabled the development of covalent inhibitors that specifically and irreversibly bind to the mutated KRAS G12C protein in its inactive GDP-bound form.

Approved Agents

Sotorasib (AMG 510, Lumakras): First approved KRAS G12C inhibitor (FDA approval 2021, EMA approval 2022) for previously treated NSCLC
Adagrasib (MRTX849, Krazati): Second approved KRAS G12C inhibitor (FDA approval 2022, EMA approval 2023) for previously treated NSCLC and colorectal cancer (in combination)

Resistance Mechanisms

A key clinical challenge is the development of resistance to KRAS G12C inhibitors. Resistance can arise through secondary KRAS mutations, KRAS gene amplification, or the activation of alternative signaling pathways. Research is therefore focusing on combination therapies and next-generation inhibitors to overcome resistance.

Clinical Relevance and Outlook

The discovery and targeted inhibition of KRAS G12C represents a milestone in precision oncology. Numerous clinical trials are investigating the use of these inhibitors in earlier lines of therapy as well as in combinations with immunotherapies, EGFR inhibitors, and other targeted agents. Testing for KRAS G12C is now a standard component of molecular tumor diagnostics in NSCLC and is increasingly recommended in other tumor entities as well.

References

Hallin J et al. - The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Cell, 2020.
Skoulidis F et al. - Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine, 2021.
European Medicines Agency (EMA) - Lumakras (Sotorasib) - Product Information, 2022. Available at: https://www.ema.europa.eu

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.